Clinical trials: Aneurysmal Subarachnoid Hemorrhages (aSAH)
Subarachnoid Hemorrhage, Aneurysmal
Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH
Safety and Pharmacokinetic study comparing intracisternal EG-1962 to enternal nimopidine in the treatment of aneurysmal subarachnoid hemorrhage.
- Trial name
- NCT02893826
- Testing
- EG-1962 (nimodipine microparticles), Enteral Nimodipine
- Where
- 4 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Edge Therapeutics Inc
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
- Trial name
- STRIVE-ON (NCT05995405)
- Testing
- GTX-104, Nimotop 30 MG Oral Capsule
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grace Therapeutics Inc.
Cerebral Vasospasm
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.
- Trial name
- NCT03611790
- Testing
- NeVa VS
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vesalio
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
The purpose of this study is to evaluate the safety and performance of the Delta system in the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) patients.
- Trial name
- NCT02129413
- Testing
- Delta system
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- Samson NeuroSciences
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care…
- Trial name
- REACT (NCT03585270)
- Testing
- Clazosentan
- Where
- 80 sites in United States, Austria and 13 more
- Volunteers
- 409 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage
Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage
The purpose of this study is to evaluate the safety and potential therapeutic benefit of use of clazosentan in reversing cerebral vasospasm (a narrowing of blood vessels in the brain due to the presence of blood in the space…
- Trial name
- REVERSE (NCT02560532)
- Testing
- Clazosentan
- Where
- 11 sites in Finland, France and 1 more
- Volunteers
- 25 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Aneurysmal Subarachnoid Hemorrhage (aSAH), Headache Disorders
Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial
Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae…
- Trial name
- SAH-BLOCK (NCT07307508)
- Testing
- Levobupivacaine Scalp block, Conventional analgesic therapy
- Where
- Qatar
- Volunteers
- 22 people
- Sponsor
- Hamad Medical Corporation
Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)
- Trial name
- DILATE (NCT06893588)
- Testing
- NEVA VS
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Vesalio